Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16N2O |
Molecular Weight | 180.2468 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CC1C(NC2=NCCO2)C3CC3
InChI
InChIKey=CQXADFVORZEARL-UHFFFAOYSA-N
InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11721891Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/rilmenidine.html | https://clinicaltrials.gov/ct2/show/NCT00892892 | https://www.ncbi.nlm.nih.gov/pubmed/16492616 | https://www.ncbi.nlm.nih.gov/pubmed/25542610 | http://agence-prd.ansm.sante.fr/html/par_eu/20110201_fr462_rilmenidine_pl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11721891
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/rilmenidine.html | https://clinicaltrials.gov/ct2/show/NCT00892892 | https://www.ncbi.nlm.nih.gov/pubmed/16492616 | https://www.ncbi.nlm.nih.gov/pubmed/25542610 | http://agence-prd.ansm.sante.fr/html/par_eu/20110201_fr462_rilmenidine_pl.pdf
Rilmenidine (brand names Albarel, Hyperium, Iterium and Tenaxum) is an imidazoline derivative used for the treatment of hypertension. Rilmenidine, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Rilmenidine shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists. Rilmenidine is as effective in monotherapy as all other first line classes of drugs, including diuretics, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and calcium antagonists. It is well tolerated and can be taken in combination for greater efficacy. Sedation and dry mouth are not prominent side effects and withdrawal hypertension is not seen when treatment is stopped abruptly. In addition to a reduction in blood pressure, Rilmenidine has been shown to improve glucose tolerance, lipid risk factors, and insulin sensitivity.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3923 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12065769 |
43.9 nM [Ki] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27265687 |
177.8 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Tenaxum Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension? | 2001 |
|
Interactions of ligands at angiotensin II-receptors and imidazoline receptors. | 2001 Feb |
|
Update on rilmenidine: clinical benefits. | 2001 Nov |
|
I1 receptors, cardiovascular function, and metabolism. | 2001 Nov |
|
Sympathetic nervous system and insulin resistance: from obesity to diabetes. | 2001 Nov |
|
Involvement of imidazoline receptors in the baroreflex effects of rilmenidine in conscious rabbits. | 2001 Sep |
|
Effects of rilmenidine and guanfacine in acute renal denervated rats. | 2002 |
|
[Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study]. | 2002 Aug |
|
Imidazoline antihypertensive drugs: a critical review on their mechanism of action. | 2002 Jan |
|
Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. | 2002 Jan |
|
Evidence for synergy between alpha(2)-adrenergic and nonadrenergic mechanisms in central blood pressure regulation. | 2002 Mar 5 |
|
Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. | 2002 Nov 15 |
|
Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. | 2002 Oct |
|
[Effect of Rilmenidine(Tenaxum) on the activity of the autonomic nervous system in patients with hypertension and asthma]. | 2003 |
|
Protective effects of centrally acting sympathomodulatory drugs on myocardial ischemia induced by sympathetic overactivity in rabbits. | 2003 Jan |
|
Effect of ethanol on reductions in norepinephrine electrochemical signal in the rostral ventrolateral medulla and hypotension elicited by I1-receptor activation in spontaneously hypertensive rats. | 2003 Sep |
|
Chronic ethanol administration attenuates imidazoline I1 receptor- or alpha 2-adrenoceptor-mediated reductions in blood pressure and hemodynamic variability in hypertensive rats. | 2004 Feb 6 |
|
Sympathetic responses to stress and rilmenidine in 2K1C rabbits: evidence of enhanced nonvascular effector mechanism. | 2004 Mar |
|
Noradrenergic modulation of XII motoneuron inspiratory activity does not involve alpha2-receptor inhibition of the Ih current or presynaptic glutamate release. | 2005 Apr |
|
Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. | 2005 Jan |
|
Rat clonidine mydriasis model: imidazoline receptors are not involved. | 2005 Jan 15 |
|
Neuronal norepinephrine responses of the rostral ventrolateral medulla and nucleus tractus solitarius neurons distinguish the I1- from the alpha2-receptor-mediated hypotension in conscious SHRs. | 2005 Jul |
|
Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper. | 2005 Mar |
|
Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension. | 2005 May 9 |
|
Role of imidazoline receptors in the anti-aversive properties of clonidine during opiate withdrawal in rats. | 2005 Oct |
|
Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension. | 2005 Sep |
|
Cause and consequences of sympathetic hyperactivity in chronic kidney disease. | 2006 |
|
Reduced hemodynamic responses to physical and mental stress under low-dose rilmenidine in healthy subjects. | 2006 Apr |
|
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. | 2006 Jan |
|
Opposite to alpha2-adrenergic agonists, an imidazoline I1 selective compound does not influence reflex bradycardia in rabbits. | 2006 Jul 30 |
|
Impact of resistant starch on body fat patterning and central appetite regulation. | 2007 Dec 12 |
|
Analysis of the role of central and peripheral alpha2-adrenoceptor subtypes in gastric mucosal defense in the rat. | 2007 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ndrugs.com/?s=rilmenidine&t=dosage
1 mg/day, up to 2 mg/day in divided doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26598394
The cytotoxic activity of rilmenidine and doxorubicin on K562 cells was measured using the MTT assay. After treatment in 96-well plates, MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-dyphenyl tetrazolium bromide) (20 μL/well) was added to each well. Sampleswere incubated for a further 4 h, followed by the addition of 100 μl of 10% SDS. Absorbance at 570 nmwasmeasured the next day.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC02AC06
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
||
|
WHO-ATC |
C02AC06
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2381
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
55679
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
54187-04-1
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
m9617
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB11738
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
DTXSID3045194
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
259-021-0
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
C75240
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
SUB10316MIG
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
RILMENIDINE
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
C032302
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
P67IM25ID8
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL289480
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
5846
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
100000080564
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY | |||
|
68712
Created by
admin on Fri Dec 15 17:30:19 GMT 2023 , Edited by admin on Fri Dec 15 17:30:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)